BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessAXIM Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome With CanChew Plus® Cannabidiol (CBD) Chewing GumBy Nasdaq OMXMar 7, 2017, 2:02 PM UTC
BusinessEarth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent StudiesBy Nasdaq OMXFeb 23, 2017, 11:45 AM UTC
BusinessAphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple SclerosisBy Nasdaq OMXFeb 22, 2017, 1:02 PM UTC
BusinessAphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple SclerosisBy Nasdaq OMXFeb 22, 2017, 1:02 PM UTC
BusinessEarth Science Tech, Inc. Enters $60B Pet Industry with its Nutraceutical Scientific High Grade Hemp CBD Oil Intended for Domestic AnimalsBy Nasdaq OMXFeb 16, 2017, 12:15 PM UTC
BusinessEarth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and TechnologyBy Nasdaq OMXFeb 6, 2017, 12:45 PM UTC
